CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 402 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01766401
NCT01766401Phase 3Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder

Forest Laboratories·interventional·Posted Jan 11, 2013·Updated Dec 18, 2019

In Brief

A Phase 3 clinical trial evaluating Placebo and Vilazadone for Generalized Anxiety Disorder. Completed, enrolled 402 participants across 30 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2013
Enrollment StartJan 31, 2013
Primary CompletionJan 29, 2014
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 13.5 years ago

Interventions

Placebodrug

Vilazadonedrug

Viibryd